Zoldem – Zolpidem Tartrate Tablets BP

1. Product Introduction

Zoldem contains zolpidem tartrate BP 10 mg in a film-coated tablet. Zolpidem is a prescription sedative-hypnotic used for short-term treatment of insomnia, particularly difficulty falling asleep, when clinically appropriate.

Healthy Life Pharma Pvt. Ltd. and Healthy Inc are named as manufacturer and exporter in the supplied product description. Manufacturing licenses, site certifications and export authorizations must be confirmed against current documents.

Safety: Zolpidem can cause serious complex sleep behaviours, including sleepwalking and sleep-driving, and can impair alertness the following day.

2. Product Specifications

Finished-product BP compliance, strength availability and any tablet scoring must be verified from approved specifications.

3. Manufacturing Technology

Production of low-dose, potent oral tablets requires validated blending, compression and film-coating processes, with appropriate controls to achieve consistent content uniformity and tablet performance. Batch segregation, line clearance and cross-contamination prevention are important GMP controls.

The supplied label confirms a film-coated 10 mg tablet. Specific manufacturing techniques, facility location and WHO-GMP status are subject to documentary verification.

4. Quality Assurance

• Identity and assay testing using validated, product-appropriate analytical methods.
• Individual-unit content uniformity and appropriate physical tablet tests.
• Dissolution and impurity testing against approved specifications.
• Stability testing to substantiate storage conditions and expiry date.
• Packaging integrity, labeling checks and controlled distribution records.

Test limits and validated methods should follow the approved product dossier; no batch results are implied here.

5. Therapeutic Uses and Mechanism

Zolpidem is a positive allosteric modulator of GABA-A receptors with a preference for certain receptor subtypes. It produces a sedative-hypnotic effect and may reduce time to sleep onset.

Indication: Short-term management of insomnia in appropriately assessed patients. Persistent insomnia should be evaluated for underlying medical, psychiatric, medication-related or sleep-related causes. Non-drug treatments such as cognitive behavioural therapy for insomnia are often preferred for chronic insomnia.

It is not an appropriate general treatment for anxiety or for long-term unsupervised use.

6. Export and Regulatory Support

Zolpidem is subject to prescription and, in some jurisdictions, controlled-substance requirements. Manufacturing, stocking, import and export may require jurisdiction-specific licenses, permits and records.

Healthy Inc is identified as exporter in the supplied material. CTD/ACTD dossiers, COPP, FSC, certificates of analysis, GMP certificates and controlled-drug permits should be requested and verified for the destination market before confirming supply.

7. Frequently Asked Questions

Q: What is the strength of Zoldem in the supplied label?
A: Zolpidem Tartrate BP 10 mg per film-coated tablet.

Q: Is zolpidem intended for long-term use?
A: It is generally intended for short-term treatment, with reassessment if insomnia persists.

Q: Can it cause unusual behaviours during sleep?
A: Yes. Complex sleep behaviours can cause serious injury. Stop taking the medicine and seek medical advice immediately if these occur.

Q: Is 5 mg confirmed for this product?
A: No. A 5 mg strength is mentioned in generic marketing content, but a product-specific 5 mg label was not supplied.

Q: Can it be taken with alcohol?
A: No. Alcohol and other sedatives increase impairment and serious safety risks.

8. Dosage and Administration

Prescription only: Dosing must be individualized by the prescriber according to the approved local product information, patient characteristics, interactions and medical history. The supplied pack is 10 mg per tablet; this does not mean 10 mg is an appropriate starting dose for every patient.

Use only immediately before bedtime when a full night of sleep (typically 7–8 hours) is available. Do not repeat a dose during the same night. Avoid alcohol and other sedatives unless specifically managed by the prescriber. Do not abruptly stop prolonged use without medical advice.

9. Side Effects and Precautions

• Serious warning: Complex sleep behaviours (sleepwalking, sleep-driving or other activities while not fully awake) can result in severe injury or death. These may occur even at recommended doses.
• Next-day drowsiness, dizziness, impaired driving, falls, confusion and memory problems can occur.
• Dependence, misuse and withdrawal symptoms are possible, particularly with prolonged use.
• Alcohol, opioids and other central nervous system depressants can increase sedation and respiratory-depression risk.
• Extra caution is needed with older adults, liver impairment, respiratory disorders, pregnancy and breastfeeding.
• Do not use in a patient with prior zolpidem-associated complex sleep behaviour or known hypersensitivity, according to relevant product labeling.

10. Storage Instructions

Store in the original packaging, protected from excess moisture and light, following the temperature limit on the approved pack label. A universal below-25°C limit and 36-month shelf life have not been independently established for the supplied Zoldem 10 mg label.

Store securely, away from children and anyone for whom the medicine was not prescribed. Follow applicable controlled-medicine storage and recordkeeping requirements.